142 related articles for article (PubMed ID: 30884088)
1. Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system.
Okamoto M; Yoshioka Y; Maeda K; Bito Y; Fukumoto T; Uesaka T; Enomoto H
Genesis; 2019 May; 57(5):e23292. PubMed ID: 30884088
[TBL] [Abstract][Full Text] [Related]
2. Increased RET Activity Coupled with a Reduction in the
Okamoto M; Uesaka T; Ito K; Enomoto H
eNeuro; 2021; 8(3):. PubMed ID: 33958373
[TBL] [Abstract][Full Text] [Related]
3. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
4. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract][Full Text] [Related]
5. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
7. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
[TBL] [Abstract][Full Text] [Related]
8. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
9. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
10. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
11. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
[TBL] [Abstract][Full Text] [Related]
12. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
14. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
15. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
16. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
18. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
19. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland.
Paszko Z; Sromek M; Czetwertynska M; Skasko E; Czapczak D; Wisniewska A; Prokurat A; Chrupek M; Jagielska A; Kozlowicz-Gudzinska I
Cancer Invest; 2007 Dec; 25(8):742-9. PubMed ID: 18058472
[TBL] [Abstract][Full Text] [Related]
20. Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.
Lian EY; Maritan SM; Cockburn JG; Kasaian K; Crupi MJ; Hurlbut D; Jones SJ; Wiseman SM; Mulligan LM
Endocr Relat Cancer; 2017 Jan; 24(1):53-69. PubMed ID: 27872141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
